scholarly journals Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting

1998 ◽  
Vol 78 (7) ◽  
pp. 940-944 ◽  
Author(s):  
M Borre ◽  
BV Offersen ◽  
B Nerstrøm ◽  
J Overgaard
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Microvessel Density ◽  
Watchful Waiting

scholarly journals High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting

PLoS ONE ◽  
2016 ◽  
Vol 11 (10) ◽  
pp. e0164016 ◽  
Author(s):  
Peter Hammarsten ◽  
Tove Dahl Scherdin ◽  
Christina Hägglöf ◽  
Pernilla Andersson ◽  
Pernilla Wikström ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Watchful Waiting ◽  
Tumor Stroma ◽  
Favourable Outcome ◽  
Caveolin 1

Urinary dysfunction appears to be the primary determinant of castration versus observation for prostate cancer patients with PSA failure

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14621-14621
Author(s):  
J. A. Zagory ◽  
C. Chang ◽  
S. Knight ◽  
E. A. Lyons ◽  
C. L. Bennett
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Watchful Waiting ◽  
Specific Antigen ◽  
Hormonal Treatment ◽  
Initial Therapy ◽  
Urinary Dysfunction ◽  
Definitive Treatment ◽  
Psa Failure ◽  
Decision Satisfaction

14621 Background: After undergoing definitive treatment for a primary localized disease, prostate cancer patients may experience a rise in their prostate specific antigen (PSA) levels. Treating PSA failure with hormonal treatment has many health related quality of life (HRQOL) implications, including urinary, bowel, sexual, and male hormonal problems. Predictors of choice between hormonal treatment versus watchful waiting have not been investigated. Methods: Patients were approached after consecutive rises in PSA levels (n = 31). Patients completed HRQOL and decision satisfaction questionnaires, and a literacy assessment. Results: Patients were between 56 and 85 years old; 55% were African American. 71% of African Americans and 50% of whites had low functional literacy. 58% of patients chose hormonal therapy to treat their PSA rise; 81% of patients reported urinary problems. All patients reported decision satisfaction (see Table). Factors associated with castration versus watchful waiting were primarily related to poor urologic function, and were not specifically prostate cancer related (dysuria, nocturia, urination frequency). Conclusions: Primary treatment of urinary dysfunction, rather than castration, should be evaluated as initial therapy for prostate cancer patients with PSA failure. [Table: see text] No significant financial relationships to disclose.

390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy

2007 ◽  
Vol 177 (4S) ◽  
pp. 130-130
Author(s):  
Markus Graefen ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Felix K.-H. Chun ◽  
Alwyn M. Reuther ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Cancer Control ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk

289: Assessment of Indirect Costs of Newly Diagnosed Prostate Cancer Patients

2007 ◽  
Vol 177 (4S) ◽  
pp. 97-97
Author(s):  
Ravishankar Jayavedappa ◽  
Sumedha Chhatre ◽  
Richard Whittington ◽  
Alan J. Wein ◽  
S. Bruce Malkowicz
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Indirect Costs ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document